BHV-1400 for IgA nephropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional trial tests the safety and tolerability of BHV-1400 in participants with biopsy-confirmed IgA nephropathy. Enrolled participants will receive BHV-1400 and undergo regular clinical and laboratory monitoring for adverse events, kidney function, and measures such as proteinuria. The trial specifically excludes secondary IgAN and other non-IgAN causes of chronic kidney disease to focus on primary IgAN. The study is being conducted at multiple U.S. sites in Connecticut and Florida.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1\. Participants must have biopsy-confirmed IgA Nephropathy

Key Exclusion Criteria:

1. Any secondary IgAN
2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Where it's running

• Site-001
  Farmington, Connecticut, United States Recruiting
• Site-003
  Miami Lakes, Florida, United States Recruiting
• Site-011
  Miami Lakes, Florida, United States Recruiting
• Site-013
  Orlando, Florida, United States Recruiting
• Site-005
  Pembroke Pines, Florida, United States Recruiting
• Site-008
  Lawrenceville, Georgia, United States Recruiting

Study contacts

• Study coordinator: Chief Medical Officer
• Email: clinicaltrials@biohavenpharma.com
• Phone: 203-404-0410

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JADE101 in IgA Nephropathy: a Phase 2 test in adults

  This Phase 2 open-label study tests JADE101 in adults with IgA nephropathy to see how safe it is and how well it works when added to standard care.

  Recruiting at 22 sites Phase 2 Jade Biosciences, Inc. · Chula Vista, California and 21 other locations · NCT07541287

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

• Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases

  This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07203404

• Nefecon (budesonide) plus ambrisentan for IgA nephropathy with proteinuria

  This test will see if combining Nefecon (a gut‑targeted budesonide) with ambrisentan can reduce urine protein and slow kidney decline in adults with IgA nephropathy who have at least 0.5 g of protein in a 24‑hour urine collection.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07030894

• Epithelial Dysmetabolism and Kidney Fibrosis in ANCA Vasculitis

  This study tests whether alterations in tubulo-interstitial metabolism relate to how quickly kidney function deteriorates in people with ANCA-associated vasculitis compared to other nephropathies.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07010250

• Which approved add-on drugs slow kidney decline in South-Asian adults with biopsy-proven IgA nephropathy?

  This trial will test whether adding one of several approved oral medications to standard care can slow kidney function loss over two years in South-Asian adults with biopsy-proven IgA nephropathy.

  Recruiting Phase 4 Christian Medical College, Vellore, India · Nadiād, Gujarat and 11 other locations · NCT06676384

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.